Found 1431 clinical trials
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
Six doses of rituximab and will be monitored the week 5 MRD and relapse rate as study outcome. Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate.
- 0 views
- 16 Feb, 2024
- 1 location
Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT
The number and clinical lifespan of stents implanted over the last twenty-five years, however, explain the fact that restenosis remains a not unusual clinical problem which is expressed as a recurrence of angina or of an acute coronary syndrome (ACS). The mechanisms involved in this restenosis are multifactorial in nature …
- 0 views
- 16 Feb, 2024
- 1 location
Reduction of COVID 19 Transmission to Health Care Professionals
The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system.
- 0 views
- 16 Feb, 2024
- 1 location
NoIAmNot Trial
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 21 Feb, 2023
enrolling Trial
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 22 Feb, 2023
COPD-ICU Multicentre Prospective Observational Register (COPD-ICU)
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 21 Feb, 2023
second sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 21 Feb, 2023
scrumsecond sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 22 Feb, 2023
- 1 location
scrumsecond sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023
scrumsecond sync
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 25 Feb, 2023